AzTrials
AzTrials

Cigarette SmokingNCT05740098

Financial Incentives for Smoking Cessation Among Mothers

A study testing Best Practices, Financial Incentives and Nicotine Replacement Therapy in people with Cigarette Smoking, run by University of Vermont at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Investigators will examine whether adding financial incentives and nicotine replacement dual therapy to current best practices for smoking cessation (i.e. referral to counseling using a telephone quit line) increases cessation rates in mothers and reduces second-hand smoke exposure in children. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Cigarette Smoking
What is being tested?
Best Practices, Financial Incentives and Nicotine Replacement Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
198 participants
Where
1 siteUnited States
Study dates
Jun 2015to Oct 2020
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Expresses interest in quitting smoking
  • Express willingness to initiate NRT
  • Mother is ≥ 18 years of age
  • Self-reported smoking ≥ 10 cigarettes per day for ≥ 1 year, biochemically verified
  • Mother has a child < 12 years of age
  • Child resides with mother full-time
Show all 11Show fewer
  • Not currently using any other tobacco cessation medications (e.g. Chantix) or NRT, or willing to stop use prior to participation in the study
  • Lives in Chittenden County, Vermont or surrounding counties
  • Plans on remaining in the geographical area for the next 12 months
  • English-speaking
  • Willing to let child participate in the study

Who cannot join

  • Failing to meet any of the above criteria
  • Has medical contraindications to NRT products
  • Meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for moderate or severe alcohol or drug dependence other than nicotine in the prior 12 months (those on opioid substitution therapy are allowed)
  • Current/past psychotic disorder
  • Being suicidal
  • Currently pregnant or trying to become pregnant in the next 12 months
  • Incarceration
  • Refusal to participate in study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Vermont Medical Center

    Burlington, Vermont, 05401

Other trials in United States

About this study

Official title: Financial Incentives for Smoking Cessation Among Disadvantaged Mothers With Young Children

Investigators will examine whether adding financial incentives and nicotine replacement dual therapy to current best practices for smoking cessation (i.e. referral to counseling using a telephone quit line) increases cessation rates in mothers and reduces second-hand smoke exposure in children. While perhaps more expensive upfront compared to best practices alone, the investigators hypothesize that this treatment approach will be a more cost-effective cessation intervention.

Read the detailed description

Smoking prevalence among disadvantaged mothers remains at strikingly high levels (40-60%). Disadvantaged women are more likely to begin smoking at an earlier age, be heavier smokers, be nicotine dependent, and fail in their efforts to quit smoking (Kandel et al., 2009). These women and their children also suffer higher rates of smoking-related adverse health consequences.

Despite widespread knowledge of the harmful effects of secondhand smoke exposure (SHSe), estimates are that 85% of children from low-income U.S. families experience chronic exposure. Children exposed to SHS are at increased risk for numerous serious health problems, including sudden infant death syndrome, more severe asthma, lower respiratory infections, and chronic middle ear disease, and maternal smoking is a particularly significant contributor to this increased morbidity and mortality. SHSe is also a substantial economic burden on the U.S. healthcare system, being estimated to increase direct medical and life-lost costs by > $5 billion annually.

Interventions developed to reduce children's SHSe have aimed to (1) decrease parental smoking around their children, (2) increase parental smoking cessation, or (3) both. Since smoking by a child's mother is a particularly significant contributor to SHSe, interventions have typically targeted smoking mothers. Regarding efforts to decrease smoking around children, studies testing relatively low-intensity interventions (e.g., written materials, brief advice) have failed to change exposure levels, while those testing more intensive interventions have had more success decreasing children's SHSe, with at least some instances of biochemically-verified changes.

Clearly, more effective smoking-cessation interventions for mothers are needed to meet the public health priority of reducing SHSe among children. The investigators recognize that maternal smoking cessation will not eliminate SHSe among children since many (~40%) live with more than one smoker. However, the evidence is clear that smoking mothers are the primary contributors to their children's SHSe, making them the obvious first target. The overarching goal of this project is to develop an efficacious, cost-effective incentive-based smoking cessation intervention that is combined with state-of-the-art smoking-cessation pharmacotherapy practices to optimize outcomes.

Participants will be 250 mothers (10 pilot and 80 per treatment condition) recruited from our university-affiliated hospital's pediatric practice, other pediatric and family medicine practices throughout the county in which our clinic is located, local offices for Women, Infants, and Children (WIC), and other recruitment strategies (e.g., ads on Facebook). Participants will be randomly assigned to one of three treatment conditions: (1) usual care for smoking cessation and protecting children from SHSe, (2) usual care combined with incentives for objectively verified smoking abstinence, and (3) usual care combined with incentives and pharmacotherapy using innovative procedures to enhance its efficacy.

The investigators believe combining pharmacotherapies with incentives could be an effective strategy for surmounting adherence problems in this population by assuring that women have regular contact with clinic staff and thereby providing staff opportunities to problem-solve obstacles that may have arisen around adherence or side effects and to regularly underscore the importance and potential benefits of using the medications as prescribed.

The investigators hypothesize that each of the interventions with incentives will increase smoking abstinence compared to usual care alone, but that the largest magnitude and most cost-effective treatment effects will be achieved by combining incentives with pharmacotherapy. They also hypothesize that (a) both incentives interventions will decrease child cotinine levels significantly more than usual care alone and (b) that SHSe levels will be significantly lower among children of abstainers than smokers.

Taken together, developing efficacious and cost-effective interventions to increase smoking cessation interventions among disadvantaged mothers and reducing SHSe among their children is an important U.S. public health priority. The financial incentives model is effective with other treatment-recalcitrant populations and we believe has the potential to meet this important public-health challenge. Behavioral-economic theory suggests that the efficacy of the cessation intervention is at least in part attributable to providing smaller, more immediate incentives for success that act to bridge the temporal delay to the larger naturalistic rewards of improved health outcomes for mother and child. The investigators will continue to investigate the behavioral-economic processes involved in smoking among disadvantaged women and in individual differences in treatment response. Lastly, there is rapidly growing interest in the use of incentives to promote healthy behavior change in disadvantaged populations. The proposed project and others like it will be important to assuring that the necessary scientific knowledge is available to support that effort.

Being tested
Best Practices, Financial Incentives, Nicotine Replacement Therapy
Keywords
Cigarette Smoking, Quit Smoking, Mothers
Medical subject headings
Cigarette Smoking

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Best PracticesBehavioural

    Also called Usual Care

    Five As plus referral to a quit line

  • Financial IncentivesBehavioural

    Also called Contingency Management

    Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.

  • Nicotine Replacement TherapyDrug

    Also called NRT

    Nicotine patches and gum/lozenge provided together for dual therapy

Study groups in NCT05740098
Study groupRoleWhat they receive
Best practicesExperimentalParticipants will receive the Five As plus a referral to a quit line.
Receives: Behavioral: Best Practices
Best practices and financial incentivesExperimentalParticipants will receive the Five As, a referral to a quit line, and financial incentives contingent on biochemically confirmed smoking abstinence
Receives: Behavioral: Best Practices; Behavioral: Financial Incentives
Best practices, financial incentives, and NRTExperimentalParticipants will receive the Five As, a referral to a quit line, financial incentives contingent on biochemically confirmed smoking abstinence, and nicotine replacement therapy (NRT) provided in the form of both nicotine patches and gum/lozenge for dual therapy.
Receives: Behavioral: Best Practices; Behavioral: Financial Incentives; Drug: Nicotine Replacement Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 7-day Point Prevalence Smoking Abstinence Levels

    Point prevalence abstinence will be defined as self-report of no smoking in the past 7 days, not even a puff, with biochemical verification via breath carbon monoxide (CO) and urine cotinine. Abstinence at the 12-week (end of treatment) and 24-week assessment will be compared between the three treatment arms.

    Measured: Collected once per woman at approximately 12- and 24- weeks following quit date in each of the three smoking arms

  2. Objective Measure of Child Secondhand Smoke Exposure (SHSe)

    SHSe will be defined as the level of cotinine measured in the urine of the youngest child at baseline, 6-, 12-, and 24-weeks following the mother's quit date. SHSe outcomes will be compared between the three treatment arms and between children of abstainers versus smokers independent of treatment condition. We hypothesize being able to detect greater reductions from baseline levels in the incentives compared to Best Practices treatment conditions and among abstainers compared to smokers. We report main effects of treatment condition as geometric means (+/- SEM) collapsed across the three assessment times for each treatment condition controlling for baseline values.

    Measured: Collected twice per child at baseline, and once at approximately 6-, 12- and 24-weeks following quit date

Secondary outcomes (4)
  1. Continuous Abstinence

    Continuous abstinence will be defined as self-report of no smoking in the past 7 days at each time point, not even a puff, with biochemical verification via breath CO and urine cotinine. Continuous abstinence from quit date through 24 week assessment will be compared between the three treatment arms.

    Measured: 24 weeks following quit date

  2. 7-day Point Prevalence Abstinence at 48-week Follow-up Assessment

    Point prevalence abstinence will be defined as self-report of no smoking in the past 7 days, not even a puff, with biochemical verification via breath CO and urine cotinine. We will use this data to estimate relapse rates across treatment arms and for use in comparing SHSe levels in children of abstainers versus smokers.

    Measured: 48 weeks following quit date

  3. Smoking Abstinence

    Biochemically-verified 7-day point-prevalence smoking abstinence.

    Measured: Assessed once per woman at 6-, 12-, 24-, and 48-weeks following quit date.

  4. Smoking Abstinence

    Biochemically-verified 7-day point-prevalence smoking abstinence.

    Measured: Collected once per woman at baseline, 6-, 12-, 24-, and 48-weeks following quit date.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2023
  2. Study startJun 2015
  3. Primary completionDec 2019
  4. Study completionOct 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
198 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05740098
Sponsor's protocol ID
5R01HD078332
Other IDs
R01HD078332
Status last verified
Feb 2023
First submitted
7 Dec 2018
Last updated
28 Jul 2023
Data monitoring committee
No
Individual data sharing
No

Publications

  • Higgins ST, Plucinski S, Orr E, Nighbor TD, Coleman SRM, Skelly J, DeSarno M, Bunn J. Randomized clinical trial examining financial incentives for smoking cessation among mothers of young children and possible impacts on child secondhand smoke exposure. Prev Med. 2023 Nov;176:107651. doi: 10.1016/j.ypmed.2023.107651. Epub 2023 Jul 30.

    PubMed 37527730

Questions about this trial

What is this clinical trial studying?

A study testing Best Practices, Financial Incentives and Nicotine Replacement Therapy in people with Cigarette Smoking, run by University of Vermont at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Jul 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

7-day Point Prevalence Smoking Abstinence Levels (time frame: Collected once per woman at approximately 12- and 24- weeks following quit date in each of the three smoking arms). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05740098, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in